加拿大魁北克省南部多机构暴发中艰难梭菌临床分离株的体外药敏试验
In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Québec, Canada.
作者信息
Bourgault Anne-Marie, Lamothe François, Loo Vivian G, Poirier Louise
机构信息
Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada.
出版信息
Antimicrob Agents Chemother. 2006 Oct;50(10):3473-5. doi: 10.1128/AAC.00479-06.
Abstract
Clostridium difficile isolates from a 2004 outbreak in Québec, Canada, were all found to be susceptible to metronidazole, vancomycin, rifampin, and meropenem but resistant to bacitracin, cefotaxime, ciprofloxacin, and levofloxacin, and most (>80%) were resistant to ceftriaxone, clarithromycin, gatifloxacin, and moxifloxacin. The predominant NAP1 isolates were susceptible to clindamycin, while the NAP2 isolates were resistant.
摘要
从加拿大魁北克2004年爆发疫情中分离出的艰难梭菌菌株，均被发现对甲硝唑、万古霉素、利福平和美罗培南敏感，但对杆菌肽、头孢噻肟、环丙沙星和左氧氟沙星耐药，并且大多数（>80%）对头孢曲松、克拉霉素、加替沙星和莫西沙星耐药。主要的NAP1菌株对克林霉素敏感，而NAP2菌株耐药。
相似文献
1
In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Québec, Canada.
Antimicrob Agents Chemother. 2006 Oct;50(10):3473-5. doi: 10.1128/AAC.00479-06.
2
Clostridium difficile infections in a Shanghai hospital: antimicrobial resistance, toxin profiles and ribotypes.
Int J Antimicrob Agents. 2009 Apr;33(4):339-42. doi: 10.1016/j.ijantimicag.2008.09.022. Epub 2008 Dec 20.
3
Diversity of moxifloxacin resistance during a nosocomial outbreak of a predominantly ribotype ARU 027 Clostridium difficile diarrhea.
Anaerobe. 2009 Dec;15(6):244-8. doi: 10.1016/j.anaerobe.2009.09.009. Epub 2009 Oct 8.
4
[Epidemiological study of Clostridium difficile strains isolated in Jean-Verdier-René-Muret hospitals from 2001 to 2007].
Pathol Biol (Paris). 2008 Nov-Dec;56(7-8):412-6. doi: 10.1016/j.patbio.2008.07.009. Epub 2008 Oct 7.
5
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
Antimicrob Agents Chemother. 2007 Aug;51(8):2674-8. doi: 10.1128/AAC.01582-06. Epub 2007 Jun 11.
6
Collateral damage. The rise of resistant C. difficile.
Science. 2008 Jul 18;321(5887):360. doi: 10.1126/science.321.5887.360.
7
Predominance and high antibiotic resistance of the emerging Clostridium difficile genotypes NAPCR1 and NAP9 in a Costa Rican hospital over a 2-year period without outbreaks.
Emerg Microbes Infect. 2016 May 11;5(5):e42. doi: 10.1038/emi.2016.38.
8
Control of an outbreak of diarrhoea in a vascular surgery unit caused by a high-level clindamycin-resistant Clostridium difficile PCR ribotype 106.
J Hosp Infect. 2011 Nov;79(3):242-7. doi: 10.1016/j.jhin.2011.06.013. Epub 2011 Aug 23.
9
[Antimicrobial susceptibility of Clostridium difficile clinical isolates collected from 2001 to 2007 in a French university hospital].
Pathol Biol (Paris). 2008 Nov-Dec;56(7-8):407-11. doi: 10.1016/j.patbio.2008.07.022. Epub 2008 Oct 8.
10
Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile.
Infect Control Hosp Epidemiol. 2007 Aug;28(8):932-40. doi: 10.1086/519181. Epub 2007 Jun 29.
引用本文的文献
1
An epidemiological surveillance study (2021-2022): detection of a high diversity of Clostridioides difficile isolates in one tertiary hospital in Chongqing, Southwest China.
BMC Infect Dis. 2023 Oct 19;23(1):703. doi: 10.1186/s12879-023-08666-2.
2
Clostridioides difficile carriage in animals and the associated changes in the host fecal microbiota.
Anaerobe. 2020 Dec;66:102279. doi: 10.1016/j.anaerobe.2020.102279. Epub 2020 Oct 3.
3
Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis.
Antimicrob Resist Infect Control. 2020 Sep 25;9(1):158. doi: 10.1186/s13756-020-00815-5.
4
Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027.
mSphere. 2019 Oct 2;4(5):e00596-19. doi: 10.1128/mSphere.00596-19.
5
Evidence of transmission of Clostridium difficile in asymptomatic patients following admission screening in a tertiary care hospital.
PLoS One. 2019 Feb 11;14(2):e0207138. doi: 10.1371/journal.pone.0207138. eCollection 2019.
6
Diagnosis of infection by toxigenic culture and PCR assay.
Iran J Microbiol. 2018 Oct;10(5):287-293.
7
Infections: A Global Overview of Drug Sensitivity and Resistance Mechanisms.
Biomed Res Int. 2018 Feb 21;2018:8414257. doi: 10.1155/2018/8414257. eCollection 2018.
8
Simultaneous detection and characterization of toxigenic Clostridium difficile directly from clinical stool specimens.
Front Med. 2018 Apr;12(2):196-205. doi: 10.1007/s11684-017-0560-5. Epub 2017 Oct 17.
9
Clostridium difficile colonization in preoperative colorectal cancer patients.
Oncotarget. 2017 Feb 14;8(7):11877-11886. doi: 10.18632/oncotarget.14424.
10
Molecular Epidemiology of Clostridium difficile Infection in Hospitalized Patients in Eastern China.
J Clin Microbiol. 2017 Mar;55(3):801-810. doi: 10.1128/JCM.01898-16. Epub 2016 Dec 14.
本文引用的文献
1
The new Clostridium difficile--what does it mean?
N Engl J Med. 2005 Dec 8;353(23):2503-5. doi: 10.1056/NEJMe058221. Epub 2005 Dec 1.
2
An epidemic, toxin gene-variant strain of Clostridium difficile.
N Engl J Med. 2005 Dec 8;353(23):2433-41. doi: 10.1056/NEJMoa051590. Epub 2005 Dec 1.
3
A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.
N Engl J Med. 2005 Dec 8;353(23):2442-9. doi: 10.1056/NEJMoa051639. Epub 2005 Dec 1.
4
Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.
Clin Infect Dis. 2005 Nov 1;41(9):1254-60. doi: 10.1086/496986. Epub 2005 Sep 20.
5
Antimicrobial susceptibility of polymerase chain reaction ribotypes of Clostridium difficile commonly isolated from symptomatic hospital patients in the UK.
J Hosp Infect. 2005 Sep;61(1):11-4. doi: 10.1016/j.jhin.2005.01.020.
6
Metronidazole for Clostridium difficile-associated disease: is it okay for Mom?
Clin Infect Dis. 2005 Jun 1;40(11):1598-600. doi: 10.1086/430317. Epub 2005 Apr 25.
7
Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.
Clin Infect Dis. 2005 Jun 1;40(11):1591-7. doi: 10.1086/430315. Epub 2005 Apr 25.
8
Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole.
Clin Infect Dis. 2005 Jun 1;40(11):1586-90. doi: 10.1086/430311. Epub 2005 Apr 25.
9
Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity.
CMAJ. 2004 Aug 31;171(5):466-72. doi: 10.1503/cmaj.1041104.
10
Clostridium difficile: a formidable foe.
CMAJ. 2004 Jul 6;171(1):47-8. doi: 10.1503/cmaj.1040836.
Zotero 插件